The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program
Pharmaceutics · 27.03.2025 · 17 (4) · 428
DOI: 10.3390/pharmaceutics17040428 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 27.03.2025. Verfasst von Stephen B Hanauer und 23 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Northwestern University Feinberg, Chicago, IL 60611, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prometheus Laboratories.
Abstract (Originalsprache)
Background/Objectives: This study aimed to establish the clinical utility of a therapeutic drug monitoring (TDM)-supported, model-informed precision dosing (MIPD) approach (precision-guided dosing [PGD]) by assessing the impact of pharmacokinetic (clearance [CL]) and clinical laboratory parameters on adalimumab (ADA) dosage adjustments during maintenance therapy for inflammatory bowel disease (IBD).
Methods
In the EMPOWER study, blood was collected at any time post-ADA injection. Pharmacokinetic (PK) testing was conducted in an accredited lab. Inputs for the PGD test included ADA concentrations, antibodies to ADA, albumin levels, and the current dosing regimen. CL was calculated using nonlinear mixed-effect models. Results were reported to health care providers (HCPs) within 3 days. HCPs’ treatment decisions were recorded and classified as treatment reduction, continuation, intensification, or ADA discontinuation. The physician global assessment (PGA) of disease activity was collected. Relationships between drug concentrations, CL, disease activity, and physician decision-making were assessed using logistic regression.
Results
A total of 213 cases were assessed by 21 HCPs. ADA treatment was intensified in 24% and discontinued in 13% of cases. An ADA concentration ≤ 10 μg/mL was associated with a 23.7-fold and 3.0-fold higher likelihood of therapy intensification and PGA > 0, respectively, compared to concentrations > 10 μg/mL. An ADA concentration < 5 μg/mL was associated with a 3.3-fold higher likelihood of treatment discontinuation. CL ≥ 0.318 L/day was associated with a 10.4-fold higher likelihood of therapy intensification. Higher CL (>0.8 L/day) was associated with a 3.5-fold and 4.2-fold higher likelihood of treatment discontinuation and PGA > 0, respectively.
Conclusions
PGD enables earlier and precise optimization of ADA dosing by predicting trough levels at any time during the therapy cycle. Optimized dosing to achieve target ADA concentrations and low clearance is crucial to mitigate therapy discontinuation and active disease in IBD patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Northwestern University Feinberg, Chicago, IL 60611, USA.
- Department of Medicine, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan 00936, Puerto Rico.
- Prometheus Laboratories Inc., San Diego, CA 92121, USA.
- Baton Rouge General Medical Center-Mid City, Baton Rouge, LA 70806, USA.
- Lenox Hill Hospital, New York, NY 10075, USA.
- GastroHealth, Coral Springs, FL 33065, USA.
ORCID-Profile: Stephen B Hanauer, Esther A Torres, Thomas C Lee, Jana G Hashash, Preetika Sinh, Bincy P Abraham
Förderung
- Prometheus Laboratories
Zitieren
APA
Hanauer, S. B., Torres, E. A., Aragon-Han, P., Chapman, J. C., Swaminath, A. C., Arai, R., Butnariu, M., Lee, T. C., Rabizadeh, S., Check, M., Barrett, T. A., Hashash, J. G., Meister, T., Yen, E. F., Kinnucan, J., Stein, D. J., Ziring, D., Shaposhnikov, R., Sinh, P., …, & Abraham, B. P. (2025). The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program. Pharmaceutics, 17(4), 428. https://doi.org/10.3390/pharmaceutics17040428
Vancouver
Hanauer SB, Torres EA, Aragon-Han P, Chapman JC, Swaminath AC, Arai R, et al. The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program. Pharmaceutics. 2025;17(4):428. doi:10.3390/pharmaceutics17040428
BibTeX
@article{Hanauer2025,
author = {Hanauer, Stephen B and Torres, Esther A and Aragon-Han, Patricia and Chapman, Jonathon C and Swaminath, Arun C and Arai, Ronen and Butnariu, Mandalina and Lee, Thomas C and Rabizadeh, Shervin and Check, Morgan and Barrett, Terrence A and Hashash, Jana G and Meister, Thomas and Yen, Eugene F and Kinnucan, Jami and Stein, Daniel J and Ziring, David and Shaposhnikov, Rimma and Sinh, Preetika and Qazi, Taha M and Yarur, Andres J and Monzur, Farah and Dervieux, Thierry and Abraham, Bincy P},
title = {The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience Program},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {4},
pages = {428},
doi = {10.3390/pharmaceutics17040428}
}
EUVIMED